Abstract
Gastroesophageal reflux disease (GERD) is an evidence-based major risk factor for the development of Barrett’s esophagus (BE) and esophageal adenocarcinoma (EA). Antireflux surgery (ARS) may offer more complete reflux inhibition than does medical treatment, because surgery also mechanically prevents duodeno-gastro-esophageal reflux. Theoretically, ARS could reduce the risk of progression for patients with BE to EA or even lead to a regression of BE and/or dysplasia.
A thorough review of the current literature suggests that regression of BE including low grade dysplasia occurs more frequently after ARS than medical treatment however, this effect is predominantly limited to short segment Barrett’s esophagus.
To date, publications including a recent systematic review have failed to demonstrate a clear consistent benefit of ARS in reducing the risk of EA compared to medical therapy. These publications have been limited by small sample sizes and poorly defined control populations specifically regarding the severity of reflux. Interestingly, the actual results of the English national population-based cohort study including 580,293 patients with GERD showed that in BE patients, ARS reduced the risk of EA (HR = 0.44; 95%CI 0.06–3.04) however, without reaching statistical significance. ARS may therefore be associated with a reduced esophageal cancer risk but still remains primarily an operation for symptomatic relief. New therapeutic options combining ablation techniques as radiofrequency ablation or endoscopic mucosal resection with ARS appear attractive but need further evaluation in large prospective trials.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Anderson LA, Watson RG, Murphy SJ, et al. Risk factors for Barrett’s oesophagus and oesophageal adenocarcinoma: results from the FINBAR study. World J Gastroenterol. 2007;13:1585–94.
Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999;340:825–31.
Cook MB, Corley DA, Murray LJ, et al. Gastroesophageal reflux in relation to adenocarcinomas of the esophagus: a pooled analysis from the Barrett’s and esophageal adenocarcinoma consortium (BEACON). PLoS One. 2014;9:e103508.
Malfertheiner P, Nocon M, Vieth M, et al. Evolution of gastro-oesophageal reflux disease over 5 years under routine medical care the ProGERD study. Aliment Pharmacol Ther. 2012;35:154–64.
Bhat S, Coleman HG, Yousef F, et al. Risk of malignant progression in Barrett’s esophagus patients: results from a large population-based study. J Natl Cancer Inst. 2011;103:1049–57.
Pohl H, Pech O, Arash H, et al. Length of Barrett’s oesophagus and cancer risk: implications from a large sample of patients with early oesophageal adenocarcinoma. Gut. 2016;65:196–201.
Hak NG, Mostafa M, Salah T, et al. Acid and bile reflux in erosive reflux disease, non-erosive reflux disease and Barrett’s esophagus. Hepato-Gastroenterology. 2008;55:442–7.
Sun D, Wang X, Gai Z, et al. Bile acids but not acidic acids induce Barrett’s esophagus. Int J Clin Exp Pathol. 2015;8:1384–92.
Fitzgerald RC, Abdalla S, Onwuegbusi BA, et al. Inflammatory gradient in Barrett’s oesophagus: implications for disease complications. Gut. 2002;51:316–22.
Fitzgerald RC. Barrett’s oesophagus and oesophageal adenocarcinoma: how does acid interfere with cell proliferation and differentiation? Gut. 2005;54(Suppl 1):i21–6.
Oelschlager BK, Barreca M, Chang L, et al. Clinical and pathologic response of Barrett’s oesophagus to laparoscopic antireflux surgery. Ann Surg. 2003;238:458–64.
Hofstetter WL, Peters JH, DeMeester TR, et al. Long-term outcome of antireflux surgery in patients with Barrett’s esophagus. Ann Surg. 2011;234:532–8; discussion 538-9
Abbas EA, Deschamps C, Cassivi SD, et al. Barrett’s esophagus: the role of laparoscopic fundoplication. Ann Thorac Surg. 2004;77:393–6.
Biertho L, Dallemagne B, Dewandre JM, et al. Laparoscopic treatment of Barrett’s esophagus: long-term results. Surg Endosc. 2007;21:11–5.
Desai KM, Soper NJ, Frisella MM, et al. Efficacy of laparoscopic antireflux surgery in patients with Barrett’s esophagus. Am J Surg. 2003;186:652–9.
Marano S, Mattacchione S, Luongo B, et al. Two-year subjective, objective, quality of life, and endoscopic follow-up after laparoscopic Nissen-Rossetti in patients with columnar-lined esophagus. Surg Laparosc Endosc Percutan Tech. 2013;23:292–8.
O’Riordan JM, Byrne PJ, Ravi N, et al. Long-term clinical and pathologic response of Barrett’s esophagus after antireflux surgery. Am J Surg. 2004;188:27–33.
Simonka Z, Paszt A, Abraham S, et al. The effects of laparoscopic Nissen fundoplication on Barrett’s esophagus: long-term results. Scand J Gastroenterol. 2012;47:13–21.
Zehetner J, deMeester SR, Ayazi S, et al. Long-term follow-up after antireflux surgery in patients with Barrett’s esophagus. J Gastrointest Surg. 2010;14:1483–91.
Ozmen V, Oran ES, Gorgun E, et al. Histologic and clinical outcome after laparoscopic Nissen fundoplication for gastroesophageal reflux disease and Barrett’s esophagus. Surg Endosc. 2006;20:226–9.
Zaninotto G, Cassaro M, Pennelli G, et al. Barrett’s epithelium after antireflux surgery. J Gastrointest Surg. 2005;9:1253–60.
Csendes A, Braghetto I, Burdiles P, et al. Late results of the surgical treatment of 125 patients with short-segment Barrett esophagus. Arch Surg. 2009;144:921–7.
Mabrut JY, Baulieux J, Adham M, et al. Impact of antireflux operation on columnar lined esophagus. J Am Coll Surg. 2003;196:60–7.
Bowers SP, Mattar SG, Smith CD, Waring JP, Hunter JG. Clinical and histologic follow-up after antireflux surgery for Barrett’s esophagus. J Gastrointest Surg. 2002;6:532–8; discussion 39
Oeberg S, Wenner J, Johansson J, et al. Barrett esophagus: risk factors for progression to dysplasia and adenocarcinoma. Ann Surg. 2005;242:49–54.
Gurski RR, Peters JH, Hagen JA, et al. Barrett’s esophagus can and does regress after antireflux surgery: a study of prevalence and predictive features. J Am Coll Surg. 2003;196:706–12.
Rossi M, Barreca M, de Bortoli N, et al. Efficacy of Nissen fundoplication versus medical therapy in the regression of low grade dysplasia in patients with Barrett esophagus. A prospective study. Ann Surg. 2006;243:58–63.
Vennalaganti P, Kanakadandi V, Goldblum JR, et al. Discordance among pathologists in the United States and Europe in diagnosis of low-grade dysplasia for patients with Barrett’s esophagus. Gastroenterology. 2017;152:564–70.
Kuramochi H, Vallbohmer D, Uchida K, et al. Quantitative, tissue-specific analysis of cyclooxygenase gene expression in the pathogenesis of Barrett’s adenocarcinoma. J Gastrointest Surg. 2004;8:1007–16; discussion 1016-7.
Vallbohmer D, DeMeester SR, Oh DS, et al. Antireflux surgery normalizes cyclooxygenase-2 expression in squamous epithelium of the distal oesophagus. Am J Gastroenterol. 2006;101:1458–66.
Oh DS, DeMeester SR, Vallbohmer D, et al. Reduction of interleukin 8 gene expression in reflux esophagitis and Barrett’s oesophagus with antireflux surgery. Arch Surg. 2007;142:554–9; discussion 559–60.
Low DE, Levine DS, Dail DH, Kozarek RA. Histological and anatomic changes in Barrett’s oesophagus after antireflux surgery. Am J Gastroenterol. 1999;94:80–5.
Oberg S, DeMeester TR, Peters JH, et al. The extent of Barrett’s oesophagus depends on the status of the lower esophageal sphincter and the degree of esophageal acid exposure. J Thorac Cardiovasc Surg. 1999;117:572–80.
Chang EY, Morris CD, Seltman AK, et al. The effect of antireflux surgery on esophageal carcinogenesis in patients with Barrett oesophagus: a systematic review. Ann Surg. 2007;246:11–21.
Zaninotto G, Parente P, Salvador R, et al. Long-term follow-up of Barrett’s epithelium: medical versus antireflux surgical therapy. J Gastrointest Surg. 2012;16:7–14.
Maret-Ouda J, Konings P, Lagergren J, Brusselaers N. Antireflux surgery and risk of esophageal adenocarcinoma: a systematic review and meta-analysis. Ann Surg. 2016;263:251–7.
Lagergren J, Ye W, Lagergren P, Lu Y. The risk of esophageal adenocarcinoma after antireflux surgery. Gastroenterology. 2010;138:1297–301.
Maret-Ouda J, Wahlin K, El-Serag HB, Lagergren J. Association between laparoscopic antireflux surgery and recurrence of gastroesophageal reflux. JAMA. 2017;318:939–46.
Ye W, Chow WH, Lagergren J, et al. Risk of adenocarcinomas of the oesophagus and gastric cardia in patients with gastroesophageal reflux diseases and after antireflux surgery. Gastroenterology. 2001;121:1286–93.
Lagergren J, Viklund P. Is esophageal adenocarcinoma occurring late after antireflux surgery due to persistent postoperative reflux? World J Surg. 2007;31:465–9.
Tran T, Spechler SJ, Richardson P, et al. Fundoplication and the risk of esophageal cancer in gastroesophageal reflux disease: a veterans affairs cohort study. Am J Gastroenterol. 2005;100:1002–8.
Lofdahl HE, Lu Y, Lagergren P, et al. Risk factors for esophageal adenocarcinoma after antireflux surgery. Ann Surg. 2013;257:579–82.
Parrilla P, Martinez de Haro LF, Ortiz A, et al. Long-term results of a randomized prospective study comparing medical and surgical treatment of Barrett’s esophagus. Ann Surg. 2003;237:291–8.
Markar SR, Arhi C, Leusink A, et al. The influence of antireflux surgery on esophageal cancer risk in England – National population-based cohort study. 2018 Paper presented at the Annual Meeting of the European Surgical Association, Trieste 2018.
Babar M, Ennis D, Abdel-Latif M, et al. Differential molecular changes in patients with asymptomatic long-segment Barrett’s esophagus treated by antireflux surgery or medical therapy. Am J Surg. 2010;199:137–43.
Smith E, Kelly JJ, Ruskiewicz AR, et al. The effect of long-term control of reflux by fundoplication on aberrant deoxyribonucleic acid methylation in patients with Barrett esophagus. Ann Surg. 2010;252:63–9.
Martinez de Haro LF, Ortiz A, Parrilla P, et al. Long-term follow-up of malignancy biomarkers in patients with Barrett’s esophagus undergoing medical or surgical treatment. Ann Surg. 2012;255:916–21.
Stein HJ, Kauer WK, Feussner H. Bile reflux in benign and malignant Barrett’s esophagus: effect of medical acid suppression and Nissen fundoplication. J Gastrointest Surg. 1998;2:333–41.
Braghetto I, Korn O, Valladares H, et al. Laparoscopic surgical treatment for patients with shortand long-segment Barrett’s esophagus: which technique in which patient? Int Surg. 2011;96:95–103.
Andrew B, Alley JB, Aguilar CE, Fanelli RD. Barrett’s esophagus before and after Roux-en-Y gastric bypass for severe obesity. Surg Endosc. 2018;32:930–6.
Gorodner V, Buxhoeveden R, Clemente G, et al. Barrett’s esophagus after Roux-en-Y gastric bypass: does regression occur? Surg Endosc. 2017;31:1849–54.
Haidry RJ, Dunn JM, Butt MA, et al. Radiofrequency ablation and endoscopic mucosal resection for dysplastic Barrett’s esophagus and early esophageal adenocarcinoma: outcomes of the UK National Halo RFA Registry. Gastroenterology. 2013;145:87–95.
Gupta M, Iyer PG, Lutzke L, et al. Recurrence of esophageal intestinal metaplasia after endoscopic mucosal resection and radiofrequency ablation of Barrett’s esophagus: results from a US Multicenter Consortium. Gastroenterology. 2013;145:79–86.
Guarner-Argente C, Buoncristiano T, Furth EE, Falk GW, Ginsberg GG. Long-term outcomes of patients with Barrett’s esophagus and high-grade dysplasia or early cancer treated with endoluminal therapies with intention to complete eradication. Gastrointest Endosc. 2013;77:190–9.
Shaheen NJ, Overholt BF, Sampliner RE, et al. Durability of radiofrequency ablation in Barrett’s esophagus with dysplasia. Gastroenterology. 2011;141:460–8.
Orman ES, Li N, Shaheen NJ. Efficacy and durability of radiofrequency ablation for Barrett’s esophagus: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2013;11:1245–55.
dos Santos RS, Bizekis C, Ebright M, et al. Radiofrequency ablation for Barrett’s esophagus and low-grade dysplasia in combination with an antireflux procedure: a new paradigm. J Thorac Cardiovasc Surg. 2010;139:713–6.
Shaheen NJ, Kim HP, Bulsiewicz WJ, et al. Prior fundoplication does not improve safety or efficacy outcomes of radiofrequency ablation: results from the U.S. RFA Registry. Gastrointest Surg. 2013;17:21–9.
Skrobić O, Simić A, Radovanović N, et al. Significance of Nissen fundoplication after endoscopic radiofrequency ablation of Barrett’s esophagus. Surg Endosc. 2016;30:3802–7.
O’Connell K, Velanovich V. Effects of Nissen fundoplication on endoscopic endoluminal radiofrequency ablation of Barrett’s esophagus. Surg Endosc. 2011;25:830–4.
Kauttu T, Räsänen J, Krogerus L, et al. Long-term results of ablation with antireflux surgery for Barrett’s esophagus: a clinical and molecular biologic study. Surg Endosc. 2012;26:1892–7.
Johnson CS, Louie BE, Wille A, et al. The durability of endoscopic therapy for treatment of Barrett’s metaplasia, dysplasia, and mucosal cancer after Nissen fundoplication. J Gastrointest Surg. 2015;19:799–805.
Shen KR, Harrison-Phipps KM, Cassivi SD, et al. Esophagectomy after antireflux surgery. J Thorac Cardiovasc Surg. 2010;139:969–75.
Chang AC, Lee JS, Sawicki KT, Pickens A, Orringer MB. Outcomes after esophagectomy in patients with prior antireflux or hiatal hernia surgery. Ann Thorac Surg. 2010;4:1015–21.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Romario, U.F., Schneider, P.M. (2019). Is There a Role for the Surgeon in the Therapeutic Management of Barrett’s Esophagus?. In: Galloro, G. (eds) Revisiting Barrett's Esophagus. Springer, Cham. https://doi.org/10.1007/978-3-319-92093-1_18
Download citation
DOI: https://doi.org/10.1007/978-3-319-92093-1_18
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-92092-4
Online ISBN: 978-3-319-92093-1
eBook Packages: MedicineMedicine (R0)